Automate Your Wheel Strategy on BCTXW
With Tiblio's Option Bot, you can configure your own wheel strategy including BCTXW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BCTXW
- Rev/Share 0.0
- Book/Share 0.179
- PB 0.3568
- Debt/Equity 0.0
- CurrentRatio 1.3693
- ROIC -0.4179
- MktCap 483097.0
- FreeCF/Share -1.2201
- PFCF -0.022
- PE -0.1109
- Debt/Assets 0.0
- DivYield 0
- ROE 66.0595
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
About BriaCell Therapeutics Corp. (BCTXW)
- IPO Date
- Website https://briacell.com
- Industry Biotechnology
- CEO William V. Williams FCPA,
- Employees 16
BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.